Ancor acquires Bonine

Ancor Capital announced the acquisition of BONINE®, an over-the-counter drug for motion sickness, by WellSpring Pharmaceutical Corporation.

The addition of BONINE® provides significant scale to its U.S.OTC nausea franchise. Its EMETROL® brand is the #1 pharmacist recommended nausea remedy, and has provided consumers with relief from nausea related to stomach flu and over-indulgence for over 50 years.

“To add a growing and innovative brand such as BONINE® provides us with the opportunity to offer a meaningful solution to help consumers prevent and treat nausea related to motion sickness. We look forward to helping people to better enjoy themselves and to be more productive, wherever their travels may take them,” said Rob Hasselman, Vice President of Sales and Marketing at WellSpring.

The latest news about Ancor Capital Partners and our portfolio companies.